3 Einträge gefunden

1. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

   1. Siegel, David
   2. Weisel, Katja
   3. Zahlten-Kumeli, Anita
   4. Medhekar, Rohan
   5. Ding, Bifeng
   6. Leleu, Xavier

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

   1. Dimopoulos, Meletios
   2. Quach, Hang
   3. Mateos, Maria-Victoria
   4. Landgren, Ola
   5. Leleu, Xavier
   6. Siegel, David
   7. Weisel, Katja

   2020 - Forschungsinformationssystem des UKE
3. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

   1. Dimopoulos, Meletios A
   2. Niesvizky, Ruben
   3. Weisel, Katja
   4. Siegel, David S
   5. Hajek, Roman
   6. Mateos, María-Victoria
   7. Cavo, Michele

   2020 - Forschungsinformationssystem des UKE